BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29772672)

  • 1. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
    Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
    Tee AR; Sampson JR; Pal DK; Bateman JM
    Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions.
    Magri L; Cambiaghi M; Cominelli M; Alfaro-Cervello C; Cursi M; Pala M; Bulfone A; Garcìa-Verdugo JM; Leocani L; Minicucci F; Poliani PL; Galli R
    Cell Stem Cell; 2011 Nov; 9(5):447-62. PubMed ID: 22056141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin and tuberous sclerosis complex.
    Wataya-Kaneda M
    J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR signaling in neural stem cells: from basic biology to disease.
    Magri L; Galli R
    Cell Mol Life Sci; 2013 Aug; 70(16):2887-98. PubMed ID: 23124271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
    Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
    J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.
    Jeong A; Wong M
    Curr Neurol Neurosci Rep; 2016 Dec; 16(12):102. PubMed ID: 27815691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
    Wong M
    Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching on mTORC1 induces neurogenesis but not proliferation in neural stem cells of young mice.
    Mahoney C; Feliciano DM; Bordey A; Hartman NW
    Neurosci Lett; 2016 Feb; 614():112-8. PubMed ID: 26812181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
    Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
    Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberous sclerosis--A model for tumour growth.
    Dodd KM; Dunlop EA
    Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
    Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.
    Zucco AJ; Pozzo VD; Afinogenova A; Hart RP; Devinsky O; D'Arcangelo G
    Mol Cell Neurosci; 2018 Oct; 92():149-163. PubMed ID: 30144504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.
    Zordan P; Cominelli M; Cascino F; Tratta E; Poliani PL; Galli R
    J Clin Invest; 2018 Apr; 128(4):1688-1706. PubMed ID: 29389670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases.
    Kassai H; Sugaya Y; Noda S; Nakao K; Maeda T; Kano M; Aiba A
    Cell Rep; 2014 Jun; 7(5):1626-1639. PubMed ID: 24857653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
    Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
    Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.
    Karalis V; Caval-Holme F; Bateup HS
    Nat Commun; 2022 Aug; 13(1):4665. PubMed ID: 35945201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.